Last reviewed · How we verify
NCT05367531
Assessment of Injectable Medication Platforms
NA trial testing Autoinjector in Overdose Antidote in 30 participants. Status unknown.
1 December 2024
Quick facts
| Lead sponsor | Canadian Forces Health Services Centre Ottawa |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 30 |
| Start date | 30 April 2022 |
| Primary completion | 1 December 2024 |
| Estimated completion | 1 January 2025 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Autoinjector
- Standard Injector
- Prefilled
Conditions studied
- Overdose Antidote — all drugs for Overdose Antidote →
- Bleeding — all drugs for Bleeding →
- Allergic Reaction — all drugs for Allergic Reaction →
Sponsor
Canadian Forces Health Services Centre Ottawa — full company profile →
Who can join
Adults 18 to 85, any sex, with Overdose Antidote or Bleeding. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background: While medical advances for in-hospital care rapidly evolve, a mainstay of effective pre-hospital care remains the ability to treat medical emergencies such as anaphylaxis, prolonged seizure, overdose, or uncontrolled bleeding, through rapid administration of appropriate medication. Autoinjectors are used globally to deliver medications in a timely manner, often in environments where immediate access to medical facilities is limited. Rapid administration of intramuscular medication delivery is essential where oral or intravenous delivery is either not possible or ineffective. The purpose of the proposed study seeks to determine the efficiency various types of medication injection administration.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05367531
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Autoinjector
Trials testing the same drug.
- NCT05339100 — Accessorized Pre-Filled Syringe to Autoinjector Pharmacokinetic Bridging Study in Anifrolumab · Phase 1 · completed
- NCT03875508 — A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Pla · Phase 3 · completed
- NCT03193957 — An Multicentre Clinical Study to Evaluate the Usability and Safety of the Autoinjector and Pre-filled Syringe of SB4 in · Phase 2 · completed
Other Canadian Forces Health Services Centre Ottawa trials
Trials by the same sponsor.
- NCT05259865 — Pharmacogenetic Testing and Chronic Pain · suspended
- NCT05474066 — ERP Changes Pre and Post Military Changes · recruiting
- NCT05469243 — Psychedelic Therapy for Wellness Studies Retrospectively · unknown
- NCT05283070 — Correlating Heart Rate Variability and Chronic Pain · unknown
- NCT05270070 — Digital Versus Traditional Booking System for Clinical Appointments · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05367531 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Canadian Forces Health Services Centre Ottawa
- Last refreshed: 8 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05367531.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing